AGT and COVID-19: The systemic activity of ACE, estimated by the angiotensin-II-to-angiotensin-I ratio (ACE-S), was markedly lower with severe versus non-severe COVID-19 (1.6 vs. 2.6), suggesting decreased functional ACE activity (Fig. 5A,B).